688065 凯赛生物
已收盘 08-10 15:00:01
资讯
新帖
简况
凯赛生物：复材无人车地板、蒙皮等产品已批量交付
证券之星 · 08-07
凯赛生物：复材无人车地板、蒙皮等产品已批量交付
凯赛生物：公司正同招商局体系内多家成员单位针对生物基聚酰胺复合材料的场景应用进行项目合作
证券之星 · 08-07
凯赛生物：公司正同招商局体系内多家成员单位针对生物基聚酰胺复合材料的场景应用进行项目合作
每周股票复盘：凯赛生物（688065）每10股派4.50元
证券之星 · 07-26
每周股票复盘：凯赛生物（688065）每10股派4.50元
凯赛生物（688065）披露2025年年度权益分派实施公告，7月22日股价下跌2.14%
证券之星 · 07-22
凯赛生物（688065）披露2025年年度权益分派实施公告，7月22日股价下跌2.14%
凯赛生物：2025年度实施差异化分红 拟派现3.24亿元
格隆汇 · 07-22
凯赛生物：2025年度实施差异化分红 拟派现3.24亿元
7月20日凯赛生物涨8.28%，科创新材料ETF博时基金重仓该股
证券之星 · 07-20
7月20日凯赛生物涨8.28%，科创新材料ETF博时基金重仓该股
每周股票复盘：凯赛生物（688065）起诉十被告索赔约9.67亿元
证券之星 · 07-19
每周股票复盘：凯赛生物（688065）起诉十被告索赔约9.67亿元
凯赛生物获得发明专利授权：“连续纤维增强生物基共聚酰胺管材及其制备方法和应用”
证券之星 · 07-15
凯赛生物获得发明专利授权：“连续纤维增强生物基共聚酰胺管材及其制备方法和应用”
凯赛生物及其子公司提起商业秘密侵权诉讼，索赔约9.67亿元
美股速递 · 07-14
凯赛生物及其子公司提起商业秘密侵权诉讼，索赔约9.67亿元
凯赛生物：提起专利侵权诉讼 索赔约9.67亿元
格隆汇 · 07-14
凯赛生物：提起专利侵权诉讼 索赔约9.67亿元
凯赛生物（688065）新增【减肥药】概念
证券之星 · 07-13
凯赛生物（688065）新增【减肥药】概念
凯赛生物：公司客户结构多元化，长链二元酸业务整体保持稳健发展
证券之星 · 07-13
凯赛生物：公司客户结构多元化，长链二元酸业务整体保持稳健发展
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
证券之星 · 07-09
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
凯赛生物：公司持续关注生物基航油等方向的技术动态与产业政策
证券之星 · 07-09
凯赛生物：公司持续关注生物基航油等方向的技术动态与产业政策
7月7日凯赛生物跌5.66%，科创新材料ETF博时基金重仓该股
证券之星 · 07-07
7月7日凯赛生物跌5.66%，科创新材料ETF博时基金重仓该股
每周股票复盘：凯赛生物（688065）2025年年度股东会决议公告
证券之星 · 06-28
每周股票复盘：凯赛生物（688065）2025年年度股东会决议公告
凯赛生物（688065）披露2025年年度股东会决议公告，6月25日股价下跌0.72%
证券之星 · 06-25
凯赛生物（688065）披露2025年年度股东会决议公告，6月25日股价下跌0.72%
股市必读：凯赛生物（688065）6月22日董秘有最新回复
证券之星 · 06-23
股市必读：凯赛生物（688065）6月22日董秘有最新回复
凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用
证券之星 · 06-22
凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用
凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证
证券之星 · 06-22
凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证
加载更多
公司概况
公司名称：
上海凯赛生物技术股份有限公司
所属行业：
化学纤维制造业
上市日期：
2020-08-12
主营业务：
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。
发行价格：
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":47.53,"timestamp":1786345201000,"preClose":48.95,"halted":0,"volume":6940998,"delay":0,"changeRate":-0.029,"floatShares":583000000,"shares":721000000,"eps":0.8173,"marketStatus":"已收盘","change":-1.42,"latestTime":"08-10 15:00:01","open":48.75,"high":48.86,"low":47.37,"amount":333000000,"amplitude":0.0304,"askPrice":47.59,"askSize":35,"bidPrice":47.53,"bidSize":107,"shortable":0,"etf":0,"ttmEps":0.8173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786411800000},"marketStatusCode":5,"adr":0,"adjPreClose":48.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1786325400000,1786332600000],[1786338000000,1786345200000]],"highLimit":53.85,"lowLimit":44.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":1.92,"roa":"--","peRate":58.1549,"roe":"0.93%","epsLYR":0.82,"committee":0.375527,"marketValue":34283000000,"turnoverRate":0.0119,"status":1,"afterMarket":{"amount":183750.98,"volume":3866,"close":47.53,"buyVolume":314,"sellVolume":0,"time":1786347237746,"indexStatus":"已收盘 08-10 15:30:00","preClose":48.95},"floatMarketCap":27728000000},"requestUrl":"/m/hq/s/688065","defaultTab":"news","newsList":[{"id":"2657761894","title":"凯赛生物：复材无人车地板、蒙皮等产品已批量交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2657761894","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657761894?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:33","pubTimestamp":1786088005,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物08月07日在投资者关系平台上答复投资者关心的问题。目前，公司的复材无人车地板、蒙皮、航空集装箱、储能箱板等产品都已经在客户层面实现批量交付；动力电池上盖产品在进行产品试制和客户测试认证；光伏边框、建筑模版、门窗、纤维筋等产品在进行工艺、产品开发并联合下游合作方推进示范、试点项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700021080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657618962","title":"凯赛生物：公司正同招商局体系内多家成员单位针对生物基聚酰胺复合材料的场景应用进行项目合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2657618962","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657618962?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:33","pubTimestamp":1786087997,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物08月07日在投资者关系平台上答复投资者关心的问题。之前，招商公众号中只要一提到绿色科技，必会提到凯赛的复材相关产品为举例，但这次没有，却提到了二氧化碳转化路线，请问公司对这个是怎么理解的？公司与招商局集团的业务合作正在稳步推进中。公司正同招商局体系内多家成员单位针对生物基聚酰胺复合材料的场景应用进行项目合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700021073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654057347","title":"每周股票复盘：凯赛生物（688065）每10股派4.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654057347","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654057347?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:20","pubTimestamp":1785003622,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，凯赛生物报收于43.19元，较上周的42.75元上涨1.03%。本周，凯赛生物7月21日盘中最高价报47.31元。本周关注点公司公告汇总：凯赛生物每10股派发现金红利4.50元（含税），股权登记日为2026年7月28日。公司公告汇总上海凯赛生物技术股份有限公司2025年年度权益分派实施公告显示，本次利润分配方案已于2026年6月25日经年度股东会审议通过。分红基数为扣除回购股份后的总股本，每10股派发现金红利4.50元（含税），合计拟派发324,040,407.30元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653668197","title":"凯赛生物（688065）披露2025年年度权益分派实施公告，7月22日股价下跌2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653668197","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653668197?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:19","pubTimestamp":1784729955,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，凯赛生物报收于44.82元，较前一交易日下跌2.14%，最新总市值为323.28亿元。近日，凯赛生物发布2025年年度权益分派实施公告。本次利润分配方案经2026年6月25日召开的2025年年度股东会审议通过。股权登记日为2026年7月28日，除权（息）日为2026年7月29日，现金红利发放日为2026年7月29日。截至公告日，公司总股本721,289,794股，扣除回购股份1,200,000股，拟派发现金红利总额324,040,407.30元（含税）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653375509","title":"凯赛生物：2025年度实施差异化分红 拟派现3.24亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653375509","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653375509?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:32","pubTimestamp":1784712752,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652008295","title":"7月20日凯赛生物涨8.28%，科创新材料ETF博时基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652008295","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652008295?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:24","pubTimestamp":1784535867,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日凯赛生物涨8.28%，收盘报46.29元，换手率1.44%，成交量8.42万手，成交额3.72亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为博时基金的科创新材料ETF博时。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["588010","688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652230685","title":"每周股票复盘：凯赛生物（688065）起诉十被告索赔约9.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652230685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652230685?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:29","pubTimestamp":1784399348,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，凯赛生物报收于42.75元，较上周的44.85元下跌4.68%。本周，凯赛生物7月13日盘中最高价报45.0元。凯赛生物当前最新总市值308.35亿元，在化学制品板块市值排名9/171，在两市A股市值排名612/5199。本周关注点公司公告汇总：凯赛生物及子公司就侵害技术秘密纠纷提起诉讼，索赔金额合计约9.67亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651865954","title":"凯赛生物获得发明专利授权：“连续纤维增强生物基共聚酰胺管材及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651865954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651865954?lang=zh_cn&edition=full","pubTime":"2026-07-15 03:27","pubTimestamp":1784057222,"startTime":"0","endTime":"0","summary":"今年以来凯赛生物新获得专利授权35个，较去年同期增加了12.9%。通过天眼查大数据分析，上海凯赛生物技术股份有限公司共对外投资了15家企业，参与招投标项目8次；财产线索方面有商标信息158条，专利信息807条，著作权信息11条；此外企业还拥有行政许可9个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500004882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144499362","title":"凯赛生物及其子公司提起商业秘密侵权诉讼，索赔约9.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144499362","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144499362?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:33","pubTimestamp":1784025196,"startTime":"0","endTime":"0","summary":"凯赛生物及其一家子公司已向法院提起诉讼，指控其商业秘密遭到侵犯，并就此寻求约9.67亿元人民币的损害赔偿。该公司表示，此次法律行动旨在保护其核心技术资产与知识产权，维护公司的合法权益与市场竞争力。诉讼的具体细节，包括被告方身份及所涉技术领域，尚未在公告中完全披露。这一索赔金额反映了公司对相关技术商业价值的评估及其对潜在损失的估算。目前，案件已进入司法程序，后续进展有待进一步关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171666","title":"凯赛生物：提起专利侵权诉讼 索赔约9.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171666","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651171666?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:58","pubTimestamp":1784023095,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119771","title":"凯赛生物（688065）新增【减肥药】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651119771?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:30","pubTimestamp":1783945821,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，7月13日凯赛生物新增概念。凯赛生物主营业务：以合成生物学等学科为基础,利用生物制造技术,从事新型生物基材料的研发、生产及销售。凯赛生物2026年一季报显示，一季度公司主营收入8.75亿元，同比上升12.73%；归母净利润1.66亿元，同比上升21.01%；扣非净利润1.48亿元，同比上升9.07%；负债率12.51%，投资收益-376.03万元，财务费用2650.62万元，毛利率36.04%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300036908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651789199","title":"凯赛生物：公司客户结构多元化，长链二元酸业务整体保持稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2651789199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651789199?lang=zh_cn&edition=full","pubTime":"2026-07-13 15:33","pubTimestamp":1783927987,"startTime":"0","endTime":"0","summary":"赢创聚酯全业务的关停，对凯赛的二元酸业务及其他生物基业务有哪些积极和消极影响？赢创是全球领先的特种化工企业，是公司在长链二元酸领域的下游客户之一。目前公司客户结构多元化，长链二元酸业务整体保持稳健发展。同时，公司目前有部分业务同赢创退出的业务处于相同赛道，有一定机会争取部分市场份额。公司将持续关注该事项进展，并根据实际情况积极应对。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300016465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944982","title":"凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944982","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650944982?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:33","pubTimestamp":1783582391,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：请问太原合成生物园的专用铁路是否已经动工？热电工程进展如何？污水处理项目进展如何？谢谢！凯赛生物回复：尊敬的投资者，您好。公司年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900021828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944938","title":"凯赛生物：公司持续关注生物基航油等方向的技术动态与产业政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650944938?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:33","pubTimestamp":1783582389,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物07月09日在投资者关系平台上答复投资者关心的问题。公司持续关注生物基航油等方向的技术动态与产业政策，对包括生物基航油在内的多种绿色能源与材料保持着密切的技术跟踪与探索，并会基于自身技术优势、市场需求变化以及国家产业政策的指引，审慎评估产业化布局与优先级。具体规划请以公司公开信息披露为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900021823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988812","title":"7月7日凯赛生物跌5.66%，科创新材料ETF博时基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649988812?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:28","pubTimestamp":1783412914,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日凯赛生物跌5.66%，收盘报46.66元，换手率0.94%，成交量5.47万手，成交额2.61亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为博时基金的科创新材料ETF博时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700027375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","588010","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646318769","title":"每周股票复盘：凯赛生物（688065）2025年年度股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2646318769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646318769?lang=zh_cn&edition=full","pubTime":"2026-06-28 01:44","pubTimestamp":1782582254,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，凯赛生物报收于47.62元，较上周的44.29元上涨7.52%。本周，凯赛生物6月23日盘中最高价报51.95元。本周关注点公司公告汇总：凯赛生物2025年年度股东会于2026年6月25日召开，所有议案均获通过。公司公告汇总上海市锦天城律师事务所就上海凯赛生物技术股份有限公司2025年年度股东会的召集程序、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果等事项出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646080962","title":"凯赛生物（688065）披露2025年年度股东会决议公告，6月25日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646080962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646080962?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:28","pubTimestamp":1782397695,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，凯赛生物报收于49.84元，较前一交易日下跌0.72%，最新总市值为359.49亿元。该股当日开盘50.15元，最高50.44元，最低48.94元，成交额达2.87亿元，换手率为0.99%。近日，凯赛生物发布《2025年年度股东会决议公告》。所有议案均获通过，无反对或否决情况。出席会议股东共256人，代表有表决权股份总数的59.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077113","title":"股市必读：凯赛生物（688065）6月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645077113?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:01","pubTimestamp":1782158519,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，凯赛生物报收于50.7元，上涨14.47%，换手率2.78%，成交量16.22万手，成交额7.74亿元。董秘最新回复投资者： 你好，贵公司产品在人形机器人和其他机器人领域是否有应用？公司高度重视股东回报，并持续关注股价表现。股份回购需综合考虑资金安排、资本开支及监管要求等因素，如有相关计划，公司将严格按照规定履行信息披露义务。当日关注点交易信息汇总：6月22日主力资金净流入32.99万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300003883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044714","title":"凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645044714?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:37","pubTimestamp":1782113862,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵公司产品在人形机器人和其他机器人领域是否有应用？未来在机器人方向应用空间？谢谢凯赛生物回复：尊敬的投资者，您好。基于凯赛生物基热塑性复合材料的优异性能，可以在机器人的关节、骨架、外壳、电池壳体以及轴承等部件应用，为机器人带来高强度、轻量化、耐疲劳以及环保性等核心价值。目前公司产品已经给客户送样。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044241","title":"凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645044241?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113780,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在去年业绩说明会上提到“光伏边框”正在进行TUV认证，一年过去了，到现在这个认证进展到什么程度了？在今年的业绩说明会互动交流中，公司提到光伏边框正在进行示范项目的产能建设，能具体介绍下这个事的情况吗凯赛生物回复：尊敬的投资者，您好。公司生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证，并计划联合战略合作方推进应用示范项目的产能建设。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786364563397,"stockEarnings":[{"period":"1week","weight":0.0756},{"period":"1month","weight":0.0892},{"period":"3month","weight":0.0389},{"period":"6month","weight":-0.0878},{"period":"1year","weight":0.0065},{"period":"ytd","weight":-0.007}],"compareEarnings":[{"period":"1week","weight":0.0281},{"period":"1month","weight":-0.0078},{"period":"3month","weight":-0.0574},{"period":"6month","weight":-0.0309},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0073}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"18523人(较上一季度增加28.48%)","perCapita":"31494股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}